Literature DB >> 26814047

Current status of the histopathological assessment, diagnosis, and reporting of colorectal neuroendocrine tumors: A Web survey from the Japanese Society for Cancer of Colon and Rectum.

Koji Ikeda1,2, Motohiro Kojima3, Norio Saito1, Naoki Sakuyama1,2, Kenichi Koushi1,2, Toshiaki Watanabe4, Kenichi Sugihara5, Tetsuo Akimoto6,2, Masaaki Ito1, Atsushi Ochiai3.   

Abstract

Although new classifications for neuroendocrine tumors were established by the World Health Organization, the current procedures and terms used in pathology laboratories are not known. A Web-based questionnaire was distributed to 491 institutions affiliated with the Japanese Society for Cancer of the Colon and Rectum, and 150 participated. The questionnaires included questions regarding routine pathological reporting, staining, and assessment of neuroendocrine tumors. Next, the time taken to assess Ki-67 index and mitotic count according to recommendation was evaluated to determine its feasibility. Most laboratories recorded diagnostic term, depth of invasion, size, lymph-vascular invasion, Ki-67 index, and mitotic count. However, only 32.2% reported tumor stage. Chromogranin A and synaptophysin were common neuroendocrine markers. D2-40 and elastica stain were frequently used to confirm lymph-vascular invasion. Only 62.1% counted more than 500 cells for the Ki-67 index, and only 17.0% counted more than 50 fields for the mitotic count, as suggested by the recommendations. Median time of 7 cases was 18.0 and 27.3 min to assess mitotic count in 50 fields with Ki-67 index in 500 and 2000 cells, respectively. For more standardized pathological reporting, education about standardized staging systems are needed in Japan. Practical and standardized procedures for mitotic index and Ki-67 index are also required.
© 2016 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  carcinoid tumor; colorectal; neuroendocrine tumor; pathological reporting; rectum

Mesh:

Substances:

Year:  2016        PMID: 26814047     DOI: 10.1111/pin.12388

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

1.  Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients.

Authors:  Kohei Ono; Eisuke Shiozawa; Nobuyuki Ohike; Tomonori Fujii; Hideki Shibata; Tetsuya Kitajima; Koichiro Fujimasa; Naoko Okamoto; Yukiko Kawaguchi; Tasuku Nagumo; Sakiko Tazawa; Mayumi Homma; Toshiko Yamochi-Onizuka; Tomoko Norose; Hitoshi Yoshida; Masahiko Murakami; Gensyu Tate; Masafumi Takimoto
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

2.  Grade G2 Rectal Neuroendocrine Tumor Is Much More Invasive Compared With G1 Tumor.

Authors:  Yi-Wei Li; Yi-Ping He; Fang-Qi Liu; Jun-Jie Peng; San-Jun Cai; Ye Xu; Ming-He Wang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

3.  Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma.

Authors:  Ran Tao; Qiang Li; Xiaofei Gao; Lilin Ma
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

4.  Neuroendocrine Tumors of the Large Intestine: Clinicopathological Features and Predictive Factors of Lymph Node Metastasis.

Authors:  Motohiro Kojima; Koji Ikeda; Norio Saito; Naoki Sakuyama; Kenichi Koushi; Shingo Kawano; Toshiaki Watanabe; Kenichi Sugihara; Masaaki Ito; Atsushi Ochiai
Journal:  Front Oncol       Date:  2016-07-18       Impact factor: 6.244

5.  Lymphovascular invasion in more than one-quarter of small rectal neuroendocrine tumors.

Authors:  Mi Jung Kwon; Ho Suk Kang; Jae Seung Soh; Hyun Lim; Jong Hyeok Kim; Choong Kee Park; Hye-Rim Park; Eun Sook Nam
Journal:  World J Gastroenterol       Date:  2016-11-14       Impact factor: 5.742

6.  Prognostic significance for colorectal carcinoid tumors based on the 8th edition TNM staging system.

Authors:  Piqing Gong; Chunhua Chen; Zhan Wang; Xukun Zhang; Wenxin Hu; Zhiqian Hu; Xinxing Li
Journal:  Cancer Med       Date:  2020-09-08       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.